Bachem schedules March 4, 2027 results for Bachem stock

Published on 10/20/2026 at 20:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bachem reported CHF 326.44 million revenue in the first half of 2026. Bachem stock costs EUR 93.15 on October 20, 2026 at 8:16 p.m. CEST.

Reporting date and operating figures

Bachem scheduled its next results for March 4, 2027.
First-half 2026 revenue reached CHF 326.44 million, while net income was CHF 50.27 million.
Bachem stock was trading at EUR 93.15 at Lang & Schwarz on October 20, 2026 at 8:16 p.m. CEST.

Fotorealistische Peptid-Produktionsanlage mit Alpenpanorama im Hintergrund — Bachem Holding AG (CH0012530207) betreibt moderne Peptid-Produktionsanlagen mit Bioreaktoren vor Schweizer Alpenpanorama, Illustration mit AI erstellt.

Bachem (CH1176493729) is scheduled to publish its next results on March 4, 2027, according to TradingView. Bachem stock was trading at EUR 93.15 at Lang & Schwarz on October 20, 2026 at 8:16 p.m. CEST.

First-half revenue reached CHF 326.44 million

The latest reported period gives investors a clear operating benchmark before the March update. Bachem generated CHF 326.44 million in revenue in the first half of 2026, compared with a consensus estimate of CHF 324.73 million, according to TradingView.

Net income was CHF 50.27 million in the first half of 2026, versus CHF 98.69 million in the previous reported period. The same source lists half-year earnings per share of CHF 0.67 against an estimate of CHF 0.47, a 42.55 percent difference calculated from those two figures.

Stock trades near its Swiss high

On the SIX, Bachem was last at CHF 86.00 on October 20, 2026 at 5:30 p.m. CEST. The quote was at the top of the reported 52-week range of CHF 48.52 to CHF 86.00, while the Lang & Schwarz price remained a separate euro quotation for investors in Germany.

Bachem had a market capitalization of CHF 6.4 billion and a price-to-earnings ratio of 43.22 on October 20, 2026. The company develops and manufactures peptides and oligonucleotides for pharmaceutical and biotechnology customers, a business profile also described by Simplify.

March 4, 2027 is the next date

The next scheduled reporting date is March 4, 2027. That date gives the market a defined checkpoint for the second-half performance, full-year figures and any update to the company's operating outlook.

Swiss listing and operating scale

Bachem is listed on the SIX under ticker BANB and is included in the SPI. Its first-half revenue, net income and earnings-per-share figures provide three separate measures for assessing the March release, while the CHF 86.00 SIX quotation places the shares at the upper end of the reported annual range.

Price remains the immediate market reference

The euro quotation for German investors was EUR 93.15 at Lang & Schwarz on October 20, 2026 at 8:16 p.m. CEST. The SIX quotation was last at CHF 86.00 on the same date at 5:30 p.m. CEST, so the two figures should be read as separate venue quotations rather than combined.

The further course of trading is shown by the continuously updated real-time quote of Bachem stock.